Orphan Star Therapeutics LLC, of New York, said it secured a commitment of $20 million from an undisclosed pharmaceutical partner. The funds will allow the company to advance its early stage pipeline of product candidates for several rare diseases, including Canavan disease, a rare genetic neurodegenerative disease that is usually fatal within the first decade of life.